

Anti-PCSK9 Antibody (Tafolecimab)

Introduction

Tafolecimab (IBI-306) is a humanized IgG2 monoclonal antibody that specifically binds PCSK-9. It also reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of low-density lipoprotein receptors, thereby enhancing the clearance of LDL-C, leading to lower LDL-C levels. Tafolecimab can be used in the study of hypercholesterolemia.

Product parameters

Alternative Names	IBI-306
Target Accession	Q8NBP7
Target	PCSK9
CAS number	2225109-03-3
Molecular Weight	145.34 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

